Member Info for Candlestick

They keep up to three-quarters of the Box Office revenue and have around 75-80% margin on food and drink.
The majority of costs are variable and they’ll have done deals with landlords to minimise/remove rent costs over lockdown. With added support with business rates and Furlough, those cinemas that are opening will be making profit.

Looking forward to seeing your maths later...

Vat cut is from both sides of the business. Looking at the website, they’re charging reduced rate for older films and the normal price for new releases, so Vat seems to be being kept on Box Office side.

Customers won’t even notice if the vat cut is passed on; once they’re in the cinema they either spend or they don’t. It’s more of an event / experience so people will buy what they want, irrespective of the price (within reason of course).

Vat is reduced to 5%, so they benefit by 15%. Have they confirmed they’re keeping it rather than passing it on? Be crazy to pass it on.

Looking their TR1s yesterday (if you believe any single bit of information on them...), EHGOS haven’t sold a single share between 19th & 29th May.

Of course, they also had their shares prior to yesterday’s announcement as they ’declared’ their holding to the company on 29th May - these guys are just making the process up as they go along.

Don’t even get me started on the conversion price, can’t believe none of the shareholder base are approaching the FCA about this.

Out of interest, what’s stopping Sona using AVCT’s Affimers instead of Native Antigen antibodies?

Will it just be due to contractual restrictions and is there a possibility that Sona/AVCT can work together if they need to upscale following any approvals?

“DIRECTORS’ AND OTHER INTERESTS
6.1 None of the Directors has any interest in the share capital of the Company or of any of its subsidiaries nor does any member of his or her family have any such interest, whether beneficial or non-beneficial.”

Don’t for a minute think that they’re following ‘the rules’.
IF they were, the last conversion would have been above 0.02, not at the ridiculous 0.01 price.
IF they were, the company would have issued the recent TR1s at the correct time.
IF they were, the company wouldn’t be releasing positive news DIRECTLY before the next share conversion. Every. Single. Time.

The only thing going in ICON’s favour is the fact that, despite the above, they’re still sitting at 0.024. And that, if there was a way to get rid of EHGOS, the price would give through the roof. But, with each of the 3 getting £200,000 per year salary (shareholders are all paying for that btw), there is no incentive for them to change anything.

Good luck though.

Appreciate this may not be the solution, but just thinking aloud...

Let’s assume (for a second) that the Sensitivity comes through at 90%, so 10% come through as false negatives.

Is there a way of selling the tests in pairs? You get 2 tests (or a single device that houses 2 tests) and you use both if you get a negative result on the first one.

As far I as I can work out, the chances of 2 false negatives (based on the assumption of 90% sensitivity) would be 1%, essentially giving us 99% sensitivity.
At 95% sensitivity, chances of 2 false negatives would be down to 0.25% (or 99.75% Sensitivity).

Just a thought..

So many it’ll make your head hurt.

They’ve converted £280,000 (for 2,411,111,110 shares - yup, that’s 2.41 billion shares in just over a month). They are committed to convert at least £2,000,000 worth.

Not sure if there is a way for them to get out of the agreement easily (why would EHGOS want to lose such easy money), but would be interested to hear if anybody knows if they can.

Unfathomable is a good description. If anything, the 0.02p conversion is the outlier, but as the closing share price never went below 0.016p (from memory), all of these conversions are total balls.

Cliveas - they’ve converted at half the price than last time. 0.01p vs 0.02p.

Like Greenspan says, this is just the start - there is another £1.72m contracted to convert. That’s going to leave you with a good number of shares in issue.

Greenspan - could you explain how they can convert at 0.01p based on the conditions within the prospectus and the RNS you’ve referred to below?

At 90%, the share price closing VWAP had to be 0.0111p; when was this?

Another 800,000 shares at just 0.01p.

Shocking attitude by the BOD.

Pashman - Currently ICON/EHGOS are tied in for AT LEAST another £1,800,000 to be drawn down. That’s just the minimum - they can swap up to £5,000,000 if they wish.
They took £50k on April 7th (555,555,555 shares)
They took £50k on April 21st (555,555,555 shares)
They took £100k on May 7th (500,000,000 shares)

Chances are that the £100k tranche can see ICON through to June, but EHGOS will be doing their best to sell into any rise with their remaining shares; they confirmed they held 870,000,000 shares on May 7th and had sold through 740,000,000 over the course of the month prior to that.

I’d imagine EHGOS will have sold through by the end of the month, if not earlier (been some big volume days), but they will then pick up another £100k’s worth soon. Then it’s all about the price they pay - no news will mean cheap conversion price as they officially only pay 90% of the lowest VWAP of the previous 15 days prior.

Still think they’ll do everything they can to bring the price down to low 0.02s so they can get some more at 0.02.

Compound - Not saying Link aren’t selling now, but they’ve not been ‘selling for many months’ here. They held 13.1m shares back in Oct 2019, last time they updated in March they still held 13.1m shares - the reduction in % was due to their dilution from the recent placing.

Alistair Smith has done an interview within 2 working days of all recent RNS publications.
However, even with new information out with the most recent, he has been conspicuous by his absence.

Possibly been asked to not do any interviews until results come through?

As is yours.

And I agree, it doesn’t look like it’s immediate or even soon; I was responding to previous posts though.

“Professor Rob Field, Director of Queen’s Anniversary Prize recipient the Manchester Institute of Biotechnology, and his team have been working with spin-out company Iceni Diagnostics to create a new test that can be used at home with the same ease as a pregnancy test. Using lateral flow, the test is able to give a yes or no answer within 20 minutes. It is hoped the test will prove valuable to medical staff, who can simply test themselves before going to work.”

It’s an at-home Test, doesn’t need to be sent anywhere - unless I’ve misread it?

Looks like Quidel’s has sensitivity around 80%

https://www.medpagetoday.com/infectiousdisease/covid19/86419

As we get towards the end (subject to ICON being a going concern), they will then start to benefit from a higher price as ICON do seem to be doing the ops side quite well.

Fully aware that’s not the case now - EHGOS still have 370m shares that they got for 0.009p, before they start on the 0.02p ones.

They would not be happy with the price dropping below 0.02p (once the 370m have gone), otherwise they’ll lose on the recent conversion. Makes sense for them to try to let the price increase by 0.01p each month. The timings this week indicate the company are working with them so it’ll likely be timed with news.

If I can get in at 0.021p (now that they’ve taken another slice of the first tranche) its defo worth a nibble but only as a complete all-or-nothing punt.